Liefke C van der Heijden
Overview
Explore the profile of Liefke C van der Heijden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanz-Sanchez J, Chiarito M, Gill G, van der Heijden L, Pina Y, Cortese B, et al.
J Soc Cardiovasc Angiogr Interv
. 2024 Aug;
1(5):100403.
PMID: 39131458
Small vessel coronary artery disease (CAD) is present in 30% to 67% of patients undergoing percutaneous coronary intervention according to different series, representing an unmet clinical need in light of...
2.
Ploumen E, Pinxterhuis T, Buiten R, Zocca P, Danse P, Schotborgh C, et al.
J Am Heart Assoc
. 2022 Nov;
11(22):e026041.
PMID: 36346050
Background In a previous trial, higher 5-year mortality was observed following treatment with biodegradable polymer Orsiro sirolimus-eluting stents (SES). We assessed 5-year safety and efficacy of all-comers as well as...
3.
Buiten R, Warta S, Ploumen E, Doggen C, van der Heijden L, Hartmann M, et al.
Coron Artery Dis
. 2020 Dec;
32(1):51-57.
PMID: 33278175
Background: Treatment of a coronary bifurcation lesion is often required in routine clinical practice, but data on the performance of very thin-strut biodegradable polymer drug-eluting stents are scarce. Methods: Comparison...
4.
Buiten R, Ploumen E, Zocca P, Doggen C, van der Heijden L, Kok M, et al.
JAMA Cardiol
. 2019 May;
4(7):659-669.
PMID: 31111862
Importance: Stenting small-vessel lesions has an increased adverse cardiovascular event risk. Very thin-strut or ultrathin-strut drug-eluting stents might reduce this risk, but data are scarce. Objective: To assess the outcome...
5.
Zocca P, Kok M, van der Heijden L, Danse P, Schotborgh C, Scholte M, et al.
Cardiovasc Drugs Ther
. 2018 Aug;
32(6):567-576.
PMID: 30143879
Purpose: Patients with high bleeding risk (HBR) who undergo percutaneous coronary intervention also have an increased risk of ischemic events and represent an overall high-risk population. The coating of durable...
6.
Zocca P, Kok M, van der Heijden L, van Houwelingen K, Hartmann M, de Man F, et al.
Int J Cardiol
. 2018 May;
268:11-17.
PMID: 29801763
Background: The prospective observational CHANGE DAPT study compared clopidogrel versus ticagrelor-based dual antiplatelet (DAPT) regimens in consecutive patients with acute coronary syndrome (ACS), treated with percutaneous coronary intervention (PCI) with...
7.
van der Heijden L, Kok M, Zocca P, Jessurun G, Schotborgh C, Roguin A, et al.
Am Heart J
. 2018 Apr;
198:25-32.
PMID: 29653644
Aim: The aim was to compare in a noninferiority trial the efficacy and safety of 2 contemporary drug-eluting stents (DESs): a novel, durable polymer-coated stent versus an established bioabsorbable polymer-coated...
8.
Kandhai-Ragunath J, Doggen C, van der Heijden L, Kok M, Zocca P, de Wagenaar B, et al.
Heart Vessels
. 2018 Mar;
33(9):978-985.
PMID: 29541845
Knowledge about the changes in endothelial function after ST-elevation myocardial infarction (STEMI) is of substantial interest, but serial data are scarce. The aim of the present study was to noninvasively...
9.
von Birgelen C, Kok M, Sattar N, Zocca P, Doelman C, Kant G, et al.
JACC Cardiovasc Interv
. 2018 Feb;
11(5):448-459.
PMID: 29454724
Objectives: This study sought to assess the prevalence and clinical impact of silent diabetes and pre-diabetes in "nondiabetic" percutaneous coronary intervention (PCI) all-comers. Background: Patients with undetected and thus untreated...
10.
van der Heijden L, Kok M, Zocca P, Sen H, Lowik M, Mariani S, et al.
J Am Heart Assoc
. 2018 Feb;
7(3).
PMID: 29382666
Background: Percutaneous coronary intervention (PCI) in patients with previous coronary artery bypass grafting (CABG) is associated with adverse clinical events. Although newer generation drug-eluting stents showed favorable short-term safety profiles,...